Phase II Randomized Trial of Radiation Therapy in Oligometastatic mCRPC Prostate Cancer (ARTO)

NCT03449719 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

174

Enrollment

OTHER

Sponsor class

Conditions

Rate of PSA Response in Oligometastatic,CRPC Undergoing SBRT in Combination With Abiraterone Acetate (AA), Compared to Patients Treated With AA Alone

Interventions

RADIATION: SBRT - Ablative radiation Therapy
DRUG: Abiraterone Acetate

Sponsor

Lorenzo Livi